PhoenixBio Co., Ltd. (TYO:6190)
Japan · Delayed Price · Currency is JPY 300.00
-2.00 (-0.66%)
Sep 16, 2026, 3:30 PM JST
PhoenixBio Market Cap
PhoenixBio has a market cap or net worth of 1.23 billion as of September 16, 2026. Its market cap has decreased by -28.09% in one year.
Market Cap
1.23B
Enterprise Value
424.20M
Revenue
1.42B
Ranking
n/a
PE Ratio
81.94
Stock Price
300.00
ChartMarket Cap Chart
Since March 18, 2016, PhoenixBio's market cap has decreased from 8.06B to 1.23B, a decrease of -84.74%. That is a compound annual growth rate of -16.39%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 16, 2026 | 1.23B | -37.60% |
| Dec 30, 2025 | 1.97B | 47.38% |
| Dec 30, 2024 | 1.34B | -23.59% |
| Dec 29, 2023 | 1.75B | -25.42% |
| Dec 30, 2022 | 2.35B | 39.61% |
| Dec 30, 2021 | 1.68B | -13.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Chordia Therapeutics | 5.33B |
| D. Western Therapeutics Institute | 5.01B |
| Ribomic | 4.52B |
| Transgenic Group | 4.33B |
| Kohjin Bio | 4.25B |
| Modalis Therapeutics | 3.76B |
| Kringle Pharma | 3.56B |
| Human Metabolome Technologies | 3.38B |